Daiichi Sankyo
4568
Performance
About Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company focused on researching, developing, and bringing medicines to patients across multiple therapeutic areas. The company emphasizes pipelines in areas such as oncology and cardiovascular diseases, and engages in open innovation and clinical trial transparency to advance medical science. With operations and research activities spanning international markets, Daiichi Sankyo aims to improve patient outcomes through innovative therapies and responsible governance.
Recent News
Hims & Hers Expands Personalized Digital Healthcare Platform
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
FDA Grants Priority Review to Ifinatamab Deruxtecan for Treated Small Cell Lung Cancer
Sutro Biopharma Inc (STRO) Q1 2026 Earnings Call Transcript
AstraZeneca and Daiichi Sankyo Secure Earlier‑Line Enhertu Approvals in South Korea
Marker Therapeutics Inc (MRKR) Q1 2026 Earnings Call Transcript
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
EU Starts Review of First-Line Enhertu for Breast Cancer
Building a Smart Oncology Pipeline with Cumulus Oncology
Well-Known Genus, Novel Method: A Post-Amgen Framework for Written Description & Enablement
A New Approach to Drugging MYC: The Application of Translation-Inhibiting Interdictors To MYC-Driven Malignancies
Interna Therapeutics Collaborates with Daiichi Sankyo to Develop MNM-Based Targeted Delivery Technologies
Blocking the IgG Highway: FcRn Biology, Approved Agents, and the Small Molecule Horizon
Piramal Pharma Solutions Partners with Ajinomoto Bio-Pharma Services to Advance ADC Development and Manufacturing
StockWatch: Trump Order Lifts Psychedelic Drug Shares
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
Daiichi Sankyo Shares Slip After Delaying Annual Earnings Report
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
FDA OKs Daiichi Sankyo/AstraZeneca’s Enhertu for Two HER2‑Positive Breast Cancer Indications
Targeting NLRP3: DFV890 and Beyond
Imagene AI Partners with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology
12 Most Profitable Blue Chip Stocks to Invest In Now
ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Two New Indications for Patients with HER2-Positive Early Breast Cancer
2025 Novel Large Molecule FDA Drug Approvals
The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
Geoff McDonough's Big Plans for NodThera's NLRP3; Enhertu Leader Steps Down at Daiichi
AstraZeneca and Daiichi Sankyo’s Enhertu Receives US FDA Approval in Early Breast Cancer for Two Indications
Pharma Pipeline Stalls for First Time in Decades: Citeline
Daiichi Ends Work on an ADC; Layoffs at GSK's R&D Unit
Daiichi Sankyo Posts 'Extraordinary Loss' Of Nearly $1B
FDA Approves Two Separate Indications for Fam-Trastuzumab Deruxtecan-Nxki in HER2-Positive Early-Stage Breast Cancer
Google Is Rolling Out AI Tools to Help Researchers Generate Hypotheses and Run Experiments Faster
MSD's Sac-TMT Delivers in First Phase 3 Readout
Daiichi Sankyo Postpones Annual Results, Stock Dips
Merck and Kelun‑Biotech’s Sac‑TMT ADC Cuts Death Risk in Phase III Endometrial Cancer Trial
FDA Approves Enhertu for Neoadjuvant and Adjuvant HER2‑Positive Early Breast Cancer
FDA Grants Priority Review to Daiichi Sankyo, Merck’s B7‑H3 ADC for Small‑Cell Lung Cancer
South Korea’s Healthcare Boom Creates New Billionaires
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
2025 Novel Small Molecule FDA Drug Approvals
Daiichi Sankyo Forecasts $1.7B Net Income on Surge in Enhertu, Datroway Sales
The Top 12 Companies Hiring in Biopharma Now
Manufacturing Hangover Drives Daiichi Sankyo Into the Red